Leucettinib 21 - Perha Pharmaceuticals
Alternative Names: LCTB-21; Leucettinib-21Latest Information Update: 02 Feb 2024
At a glance
- Originator Perha Pharmaceuticals
- Class Antidementias; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease; Down syndrome
Most Recent Events
- 22 Jan 2024 Preclinical trials in Alzheimer's disease in France (unspecified route)
- 22 Jan 2024 Preclinical trials in Down syndrome in France (unspecified route)
- 18 Jan 2024 Phase-I clinical trials in Alzheimer's disease in France (PO) (NCT06206824)